Azitra (AZTR) Total Non-Current Liabilities (2022 - 2025)
Azitra (AZTR) posted Total Non-Current Liabilities of $1.2 million for Q4 2025, down 39.43% on a QoQ basis from $2.0 million in Q3 2025, and down 26.26% year-over-year from $1.7 million in Q4 2024.
Azitra (AZTR) Total Non-Current Liabilities (2022 - 2025) Analysis & Trends
Azitra's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 26.26% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 26.26% YoY) and the FY2025 annual result came in at $1.2 million, down 26.26% from the prior year.
- Total Non-Current Liabilities was $1.2 million for Q4 2025 at Azitra, down from $2.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.7 million in Q4 2022 and bottomed at $1.2 million in Q4 2025.
- A 4-year average of $2.5 million and a median of $1.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 77.58% — and 2025, when it increased 17.59%.
- Azitra's Total Non-Current Liabilities stood at $9.7 million in 2022, then sank by 77.58% to $2.2 million in 2023, then declined by 23.39% to $1.7 million in 2024, then retreated by 26.26% to $1.2 million in 2025.
- Business Quant data shows AZTR's Total Non-Current Liabilities at $1.2 million in Q4 2025, $2.0 million in Q3 2025, and $1.7 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | 107.80 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 19.49 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 1.98 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 5.87 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 7.32 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | - |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | 40.00 Mn |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 4.05 Bn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 746.94 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.43 Mn |
| Dec 31, 2022 | 9.66 Mn |